Does an engineered peptide antagonist against periostin reduce doxorubicin resistance in breast cancer?
An engineered peptide antagonist against periostin shows potential to overcome doxorubicin resistance in breast cancer.
This finding supports that anti-PN peptide is expected to be used in the development of peptide therapy to reduce PN-induced chemoresistance in BCA.
Oo et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: